2. Search Result
Search Result
Results for "

lipid peroxidation accumulation

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146683
    KS106

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS106
  • HY-146682
    KS100

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS100 is a potent ALDH inhibitor with IC50s of 230, 1542, 193 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS100 shows antiproliferative and anticancer effects with low low toxic. KS100 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS10600 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS100
  • HY-139369
    QD394

    		Reactive Oxygen Species Cancer
    QD394 is a reactive oxygen species (ROS) inducer that can induce lipid peroxidation, increase intracellular ROS accumulation, inhibit STAT3 phosphorylation, and induce ferroptosis .
    QD394
  • HY-N0717
    L-Valine
    3 Publications Verification

    Valine

    		 Bacterial Arginase Akt Infection
    L-Valine (Valine) is a new nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine
  • HY-N0717R
    L-Valine (Standard)

    		Arginase Akt Bacterial Others
    L-Valine (Standard) is the analytical standard of L-Valine. This product is intended for research and analytical applications. L-Valine (Valine) is a new nonlinear semiorganic material. L-Valine standrd causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine standrd inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine (Standard)
  • HY-163654
    Ferroptosis-IN-8

    		Ferroptosis Cancer
    Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .
    Ferroptosis-IN-8
  • HY-161928
    GPX4 activator 1

    		Glutathione Peroxidase Ferroptosis Cancer
    GPX4 activator 1 (Compound A9) is a allosteric activator of GPX4 (Kd = 5.86 μM, EC50 = 19.19 μM). GPX4 activator 1 can selectively act on ferroptosis and prevent the accumulation of intracellular lipid peroxides caused by ferroptosis inducers .
    GPX4 activator 1
  • HY-168042
    Antibacterial agent 243

    		Bacterial Fungal Infection
    Antibacterial agent 243 is an antibacterial agent, with EC50 values of 0.64 mg/L for Valsa mali, 26 mg/L for allicin, and 0.33 mg/L for tebuconazole. Antibacterial agent 243 can induce hyphal shrinkage and collapse, trigger the accumulation of reactive oxygen species inside cells, regulate antioxidant enzyme activity, initiate lipid peroxidation, and ultimately cause irreversible oxidative damage to Valsa mali cells .
    Antibacterial agent 243
  • HY-162106
    PROTAC GPX4 degrader-2

    		Ferroptosis PROTACs Glutathione Peroxidase Cancer
    PROTAC GPX4 degrader-2 (compound 18a) is a proteolysis targeting chimeras (PROTACs) that can degrade glutathione peroxidase 4 (GPX4), with the DC50, 48h value of 1.68 μM. PROTAC GPX4 degrader-2 induces the accumulation of lipid peroxides and mitochondrial depolarization, subsequently triggering ferroptosis. PROTAC GPX4 degrader-2 has anti-proliferative effect .
    PROTAC GPX4 degrader-2
  • HY-161388
    NSCLC-IN-1

    		Ferroptosis Mitophagy Cancer
    NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca 2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent .
    NSCLC-IN-1
  • HY-170509
    Ferroptosis-IN-17

    		Ferroptosis Glutathione Peroxidase Cardiovascular Disease Neurological Disease Cancer
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases .
    Ferroptosis-IN-17
  • HY-170959
    NYY-6a

    		Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-172092
    BG11

    		Apoptosis Ferroptosis Cancer
    BG11 induces the accumulation of Fe 2+ and intracellular lipid peroxides, induces ferroptosis. BG11 regulates the expression of Bax and Bcl-2 proteins, and induces apoptosis in MDA-MB-231 cell. BG11 arrests the cell cycle at G0/G1 and S phase, inhibits the proliferation of TNBC cancer cell (IC50 for MDA-MB-231 and BT549 is 0.49 μM and 0.52 μM), and inhibits the cell migration and invasion. BG11 exhibits antitumor efficacy in mouse models .
    BG11
  • HY-117049
    Leucettine L41
    1 Publications Verification

    		 CDK DYRK Neurological Disease
    Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) . Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model .
    Leucettine L41

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: